ABO Blood Group and Risk of Pancreatic Cancer in a Turkish Population in Western Blacksea Region

  • Engin, Huseyin ;
  • Bilir, Cemil ;
  • Ustun, Hasan ;
  • Gokmen, Ayla
  • Published : 2012.01.31


Background: We aimed to investigate the relationship between blood groups and pancreatic cancer in a Turkish population in Western Blacksea region. Methods: This is a retrospective study. Zonguldak Karaelmas University outpatient oncology clinic records were screened for the period between 2004 and 2011. Results: The median age of patients were 56 (${\pm}16$) and 132 of 633 study population had pancreatic cancer. Pancreatic cancer patients had significantly higher rates of blood group A compared to controls (OR 1.8, 95%CI, p 0.005). Rates of blood group AB was significantly lower than the control group (OR 0.37, 95% CI, p 0.04). The median survival (IR) time in subjects having the blood groups A, B, AB and O were 7.0 (1-28), 7.0 (2-38), 10 (2-36) and 9.0 (2-48) months respectively; the blood group 0 had significantly higher overall survival (OS) compared to the non-0 groups (p 0.04). Conclusions: Pancreatic cancer patients had more common blood group A in our population. Moreover, blood group AB appeared to be a protective factor against pancreatic cancer in our population. Blood group 0 had a significantly longer survival compared to non-0, regardless of prognostic factors.


Blood group;pancreatic cancer;survival;Turkey


  1. Amundadottir L, Kraft P, Stolzenberg Solomon RZ, et al (2009). Genome-wide association study identifies variants in the ABO locus associated with susceptibility to pancreatic cancer. Nat Genet, 41, 986-90.
  2. Annese V, Minervini M, Gabbrielli A, et al (1990). ABO blood groups and cancer of the pancreas. Int J Pancreatol, 6, 81-8.
  3. Aird I, Bentall HH, Roberts JA(1953). A relationship between cancer of stomach and the ABO blood groups. BMJ, 1, 799-801.
  4. Ben Q, Wang K, Yuan Y, Li Z (2011). Pancreatic cancer incidence and outcome in relation to ABO blood groups among Han Chinese patients: a case-control study. Int J Cancer, 128, 1179-86.
  5. Hakomori S (1999). Antigen structure and genetic basis of histo-blood groups A, B and O: their changes associated with human cancer. Biochim Biophys Acta, 1473, 247-66.
  6. Itzkowitz SH, Yuan M, Ferrell LD, et al (1987). Cancerassociated alterations of blood group antigen expression in the human pancreas. J Natl Cancer Inst, 79, 425-34.
  7. Jemal A, Siegel R, Ward E, et al (2009). Cancer statistics, 2009. CA Cancer J Clin, 59, 225-49.
  8. Lowenfels AB, Maisonneuve P (2006). Epidemiology and risk factors for pancreatic cancer. Best Pract Res Clin Gastroenterol, 20, 197-209.
  9. Melzer D, Perry JR, Hernandez D, et al (2008). A genome-wide association study identifies protein quantitative trait loci (pQTLs). PLoS Genet, 4, e1000072.
  10. Newell GR, Gordon JE , Monlezun AP (1974). ABO blood groups and cancer. J Natl Cancer Inst, 52, 1425-30.
  11. Roseman S (2001). Reflections on glycobiology. J Biol Chem, 276, 41527-42.
  12. Sant M, Allemani C, Santaquilani M, et al (2009). EUROCARE-4. Survival of cancer patients diagnosed in 1995-1999. Results and commentary. Eur J Cancer, 45, 931-91.
  13. Sener SF, Fremgen A, Menck HR, et al (1999). Pancreatic cancer: a report of treatment and survival trends for 100,313 patients diagnosed from 1985-1995, using the National Cancer Database. J Am Coll Surg, 189, 1-7.
  14. Souto JC, Almasy L, Muñiz Diaz E, et al (2000). Functional effects of the ABO locus polymorphism on plasma levels of von Willebrand factor, factor VIII, and activated partial thromboplastin time. Arterioscler Thromb Vasc Biol, 20, 2024-8.
  15. Vioque J, Walker AM (1991). Pancreatic cancer and ABO blood types: a study of cases and controls. Med Clin, 96, 761-4.
  16. Vogel F (1970). Controversy in human genetics. ABO blood groups and disease. Am J Hum Genet, 22, 464-75.
  17. Wolpin BM, Chan AT, Hartge P, et al (2009). ABO blood group and the risk of pancreatic cancer. J Natl Cancer Inst, 101, 424-31.
  18. Zhang S, Zhang HS, Cordon Cardo C, et al (1997). Selection of tumor antigens as targets for immune attack using immunohistochemistry: II. Blood group-related antigens. Int J Cancer, 73, 50-6.<50::AID-IJC9>3.0.CO;2-0

Cited by

  1. Is There an Association between Blood Group and Survival in Pancreatic Cancer? vol.13, pp.12, 2012,
  2. Evaluation of ABO blood group as a prognostic marker in renal cell carcinoma (RCC) vol.113, pp.5b, 2013,
  3. ABO Blood Groups are Not Associated with Treatment Response and Prognosis in Patients with Local Advanced Non-Small Cell Lung Cancer vol.14, pp.6, 2013,
  4. ABO blood groups and pancreatic cancer risk and survival: Results from the PANcreatic Disease ReseArch (PANDoRA) consortium vol.29, pp.4, 2013,
  5. Association of NRF2 Polymorphism with Cholangiocarcinoma Prognosis in Thai Patients vol.15, pp.1, 2014,
  6. Clinical, Laboratory Biomarkers and Imaging Findings of Pancreatic Adenocarcinoma in Iran vol.15, pp.10, 2014,
  7. Epidemiology of Pancreatic Cancer in Vojvodina Province in Serbia vol.15, pp.24, 2015,
  8. Association between ABO Genotype and Risk of Hepatocellular Carcinoma in Koreans vol.16, pp.7, 2015,
  9. Prognostic Correlations between ABO Blood Group and Pre-Treatment Plasma Epstein-Barr Virus DNA in Patients with Nasopharyngeal Carcinoma Receiving Intensity-Modulated Radiotherapy vol.11, pp.11, 2016,
  10. Pancreatic cancer vol.19, pp.3, 2016,
  11. ABO blood group is a predictor of survival in patients with laryngeal cancer vol.35, pp.1, 2016,
  12. Establishment of cholangiocarcinoma cell lines from patients in the endemic area of liver fluke infection in Thailand vol.39, pp.11, 2017,
  13. Associations between ABO blood groups and pancreatic ductal adenocarcinoma: influence on resection status and survival vol.6, pp.7, 2017,
  14. Prognostic value of ABO blood group in southern Chinese patients with established nasopharyngeal carcinoma vol.109, pp.9, 2013,
  15. The Inhibition Kinetics and Potential Anti-Migration Activity of NQO1 Inhibitory Coumarins on Cholangiocarcinoma Cells vol.18, pp.1552-695X, 2019,
  16. Chemiluminescent Probe for the In Vitro and In Vivo Imaging of Cancers Over-Expressing NQO1 vol.131, pp.6, 2019,
  17. Chemiluminescent Probe for the In Vitro and In Vivo Imaging of Cancers Over-Expressing NQO1 vol.58, pp.6, 2019,